pipette
ENEnglish

Rescue treatment for medium vessel occlusion by intra-arterial tenecteplase: the RESCUE-TNK randomized clinical trial

Zi-Ai Zhao, Shouchun Wang, Ming Wei, Gao-Peng Xing, Wei Li, Jing Qiu, Xiaolong Li, Xian‐Hui Sun, Liang Liu, Tian-Yi Zheng, Jue Wang, Rong Yin, Xiaolu Sun, Yi Zhang, Yu Cui, Thanh Ngoc Nguyen, Dawei Chen

Revista con revisión por paresUso en el mundo real

En palabras de los autores

In patients with acute ischemic stroke caused by medium vessel occlusion (MeVO), intra-arterial tenecteplase may offer a targeted strategy to improve recanalization; we hypothesized that intra-arterial tenecteplase would increase successful reperfusion compared with standard care with a comparable safety profile. This phase 2, prospective, randomised, open-label, blinded-endpoint, multicentre study aims to assess the efficacy and safety of intra-arterial tenecteplase for patients with acute ischemic stroke caused by MeVO. Patients with MeVO were randomly (1:1) assigned to receive intra-arterial tenecteplase or standard care. The primary outcome was successful reperfusion of medium vessel occlusion. A total of 80 patients were randomized to either the tenecteplase group (n = 41) or control group (n = 39). Successful reperfusion reached 61.0% (25/41) in the tenecteplase group versus 28.2% (11/39) in the control group (unadjusted odds ratio 3.98, 95% CI 1.56-10.16; P = 0.004). Symptomatic intracranial hemorrhage within 24 h was similar between the tenecteplase and control groups. This work suggests that intra-arterial tenecteplase significantly increased the probability of successful reperfusion compared with standard care, with a comparable safety profile in this stroke population. (Funded by Shenyang Science Tech Project and hospital-initiated grants; ClinicalTrials.gov registration: NCT05657470) Medium-vessel occlusion accounts for a substantial proportion of acute ischemic stroke cases, yet optimal reperfusion treatment strategies remain unclear for patients ineligible for mechanical endovascular thrombectomy. Here, the authors show that intra-arterial tenecteplase significantly increases reperfusion rates for medium-vessel occlusion with acceptable safety, although statistically-significant improvements in 90-day functional outcomes were not detected in this phase-2 randomized trial.

Resultado principalLimitación que admiten los autores

Apareció: domingo, 8 de noviembre. Nature Communications. Revista con revisión por pares.

DOI: 10.1038/s41467-026-79062-y